A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Bimatoprost Solution 0.03%, 0.1%, and 0.3% Compared with Vehicle in Men with Androgenic Alopecia with an Open-label Active Comparator (Minoxidil 5%) Group.
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2016
At a glance
- Drugs Bimatoprost (Primary) ; Minoxidil
- Indications Male pattern baldness
- Focus Therapeutic Use
- Sponsors Allergan
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Jul 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.